KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EPS (Basic): 2018-2025

Historic EPS (Basic) for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $0.24.

  • Aurinia Pharmaceuticals' EPS (Basic) rose 140.00% to $0.24 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.58, marking a year-over-year increase of 486.67%. This contributed to the annual value of $0.04 for FY2024, which is 107.41% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' EPS (Basic) stood at $0.24, which was up 50.00% from $0.16 recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' EPS (Basic) registered a high of $0.24 during Q3 2025, and its lowest value of -$0.40 during Q1 2021.
  • Its 3-year average for EPS (Basic) is $0.01, with a median of $0.01 in 2024.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' EPS (Basic) crashed by 316.67% in 2021, and later soared by 1,500.00% in 2025.
  • Aurinia Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$0.25 in 2021, then rose by 28.00% to -$0.18 in 2022, then declined by 5.56% to -$0.19 in 2023, then surged by 105.26% to $0.01 in 2024, then spiked by 140.00% to $0.24 in 2025.
  • Its EPS (Basic) stands at $0.24 for Q3 2025, versus $0.16 for Q2 2025 and $0.17 for Q1 2025.